Interim Consolidated Financial Statements

For the three months ended May 31, 2021 and 2020

(Expressed in Canadian Dollars)

(Unaudited)

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(Expressed in Canadian Dollars)

	May 31, 2021	Feb 28, 2020
ASSETS	\$	\$
Current		
Cash	1,032,818	7,769
GST and taxes recoverable	37,314	4,205
Prepaid expenses and deposits (Note 6)	367,931	27,867
	1,438,063	39,840
Amounts receivable	-	106,846
Intangible assets (Note 5)	1	1
	1,438,064	146,687
LIABILITIES		
Current		
Accounts payable	524,115	861,532
Deferred revenue	74,984	74,984
Amounts payable (Note 7)	· -	2,086,106
	599,099	2,463,160
Non-current		
Convertible note (Note 11)	737,500	550,962
Loans payable (Note 12)	60,000	60,000
	1,396,599	3,633,583
EQUITY (DEFICIENCY)		
Share capital (Note 9)	5,209,018	630,160
Contributed surplus	1,225,583	1,214,574
Equity portion of convertible note	-	40,484
Deficit	(6,393,136)	(5,372,113)
	41,465	(3,486,895)
	1,438,064	146,687

NATURE OF OPERATIONS AND GOING CONCERN (Note 1) COMMITMENT (Note 14)

Approved and authorized for issuance on behalf of the Board on July 28, 2021:

/s/ Ryan Selby Director

/s/ Aaron Bowden Director

CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

(Expressed in Canadian Dollars)

	Three Months Ended May 31, 2021	Three Months Ended May 31, 2020
	\$1,2021	\$
EXPENSES		
Accretion and interest expense	26,262	22,658
Management fees (Note 7)	236,345	49,400
Advertising and promotion	384,234	-
Office and miscellaneous	26,326	8,631
Professional fees	118,117	32,589
Research & Development	211,166	-
Share-based compensation (Note 9)	18,573	-
Travel and entertainment	-	1,650
Net loss for the period	(1,021,023)	(114,927)
Other Items		
Other	-	
Net and comprehensive loss for the period	(1,021,023)	(114,927)
Loss per share (basic and diluted)	(0.07)	(0.00)
Weighted average number of common shares outstanding	13,757,419	42,783,920

CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY)

(Expressed in Canadian Dollars)

	Common S	hares				
	Number	Amount	Contributed Surplus	Equity Portion of Convertible Note	Deficit	Total
		\$	\$	\$	\$	\$
Balance as at February 29, 2020 Share-based compensation	42,783,920	630,160	1,175,348	35,385	(1,259,313)	581,480 -
Convertible note Comprehensive loss	- -	- -	-	5,099 -	- (114,927)	5,099 (114,927)
Balance as at May 31, 2020	42,783,920	630,160	1,175,348	40,484	(1,374,240)	471,652
Balance as at February 28, 2021	6,970,286	3,026,518	1,207,010	48,049	(5,372,113)	(1,090,537)
Private placement	2,500,000	1,000,000	-,_0.,0.0	-	(0,01=,110)	1,000,000
Shares issued for cash	26,500,000	1,175,000	-	-	-	1,175,000
Special warrants	150,000	7,500	-	-	-	7,500
Share-based compensation	-	-	18,573	-	-	18,573
Convertible note				(48,049)		(48,049)
Comprehensive loss	-	-		<u>-</u>	(1,021,023)	(1,021,023)
Balance as at May 31, 2021	36,120,286	5,209,018	1,225,583	-	(6,393,136)	41,465

PODA LIFESTYLE AND WELLNESS LTD. CONSOLIDATED INTERIM STATEMENTS OF CASH FLOW

FOR THE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

	2021	2020
CASH PROVIDED BY (USED IN):	\$	\$
, ,		
OPERATING ACTIVITIES		
Net loss for the period	(1,021,023)	(89,733)
Items not affecting cash		
Accretion	(49,010)	5,020
Share-based compensation	18,573	-
Changes in non-cash working capital balances:		
GST and taxes recoverable	73,737	2,562
Prepaid expenses and deposits	(340,064)	3
Customer advances	-	74,984
Accounts payable	(337,416)	77,375
Cash provided (used) by operating activities	(1,655,203)	70,211
INVESTING ACTIVITIES		
Intangible assets	_	(115,792)
		_
Cash used in investing activities	<u>-</u>	(115,792)
FINANCING ACTIVITIES		
Proceeds from convertible note	187,500	50,000
Issuance of shares to extinguish liabilities ·	(2,086,106)	-
Proceeds from the issuance of common stock	4,578,858	<u>-</u>
Cash provided by financing activities	2,680,253	50,000
CHANGE IN CASH DURING THE PERIOD	1,025,049	4,419
CASH, BEGINNING OF YEAR	7,769	32,800
CASH, END OF PERIOD	1,032,818	37,219
SUPPLEMENTAL CASH DISCLOSURES		
Interest paid	\$ -	\$ 12,263
Income taxes paid	\$ -	\$ -

The accompanying notes are an integral part of these consolidated interim financial statements.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

1. NATURE OPERATIONS AND GOING CONCERN

PODA Lifestyle & Wellness Ltd. (the "Company") was incorporated in the Province of British Columbia on July 6, 2018, under the Business Corporations Act of British Columbia under the name Gamora Capital Corp. On March 11, 2021, the Company changed its name to PODA Lifestyle & Wellness Ltd. The Company's principal business activity is the design, development and production of a new and improved heat-not-burn technology for the consumption of tobacco and other materials.

The Company's head office is located at 666 Burrard St, Vancouver, BC V6C 2Z7.

The accompanying consolidated interim financial statements comprise the financial statements of the Company and its legal subsidiary, Poda Technologies Ltd. ("Poda"). The Company and Poda entered into an Arrangement Agreement (Note 8) on February 8, 2021, pursuant to which the Company, by way of a court approved plan of arrangement under the provisions of Division 5 of Part 9 of the BCBCA acquired all of the issued and outstanding PODA Shares in exchange for Preferred Shares to be issued as consideration pursuant to the Plan of Arrangement (the "Arrangement").

The Arrangement resulted in the shareholders of Poda acquiring control of the Company. Therefore, the transaction, has been accounted for as an acquisition of the Company by Poda. The transaction has been accounted for as a reverse take-over ("RTO"). As the Company does not meet the definition of a business as defined by International Financial Reporting Standards ("IFRS") 3, it has been accounted for as a share-based payment transaction in accordance with IFRS 2.

These consolidated interim financial statements have been prepared on the basis of accounting principles applicable to a going concern, which presumes that the Company will realize its assets and discharge its liabilities in the normal course of business for at least the next twelve months. The Company does not have any working capital and has not earned income from inception. These factors indicate the existence of a material uncertainty that casts significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue as a going concern and to realize the carrying value of its assets and discharge its liabilities, when due, is dependent upon the Company's ability to execute its business plan which may require additional financing. The timing and availability of additional financing will be determined largely by the performance of the Company and market conditions and there is no certainty that the Company will be able to raise funds as they are required in the future.

These consolidated interim financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern basis was not appropriate for these consolidated interim financial statements, then adjustments would be necessary to reflect these consolidated interim financial statements on a liquidation basis which could differ from accounting principles applicable to a going concern.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. At this point, the impact on the Company has been minimal. The Company continues to monitor the situation and is taking all necessary precautions in order to follow rules and best practices as set out by the federal and provincial governments.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

2. BASIS OF PREPARATION

a) Statement of compliance

These consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting. In preparation of these consolidated interim financial statements, the Company has consistently applied the same accounting policies disclosed in the Poda's audited annual financial statements for the year ended January 31, 2021(see Note 8), with the exception of the new accounting standards adopted in the current year, as described below.

These consolidated interim financial statements were authorized for issue by the Board of Directors on July 28, 2021.

b) Basis of measurement

These consolidated interim financial statements have been prepared on a historical cost basis except for certain non-current assets and financial instruments, which are measured at fair value, as disclosed in Note 3.

The functional and presentation currency of the Company and its subsidiaries is the Canadian dollar.

The preparation of these consolidated financial statements in compliance with IFRS requires management to make certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The areas involving a higher degree of

judgment of complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 3.

c) Basis of consolidation

These consolidated interim financial statements include the financial statements of the Company and the subsidiary controlled by the Company. Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of the subsidiary are included in the consolidated financial statements from the date on which control is transferred to the Company until the date that control ceases. All intercompany transactions and balances have been eliminated on consolidation.

Company	Place of Incorporation	Percentage of ownership
Poda Technologies Ltd.	Canada	100%
California Distribution Company Ltd.	Canada	100%
1237225 BC Ltd.	Canada	100%
		-

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES

a) Significant accounting estimates and judgements

The preparation of these consolidated interim financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. These consolidated interim financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated interim financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the financial position reporting date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

Significant accounting estimates

- i. the measurement of deferred income tax assets and liabilities; and
- ii. inputs used in impairment calculations.

Significant accounting judgment

- i. the evaluation of the Company's ability to continue as a going concern;
- ii. the evaluation on whether or not an acquisition of a business is considered a business combination or an asset acquisition;
- iii. assessment of indications of impairment; and
- iv. the determination of categories of financial assets and financial liabilities.

b) Income taxes

Deferred tax assets and liabilities are recognized where the carrying amount of an asset or liability differs from its tax base, except for taxable temporary differences arising on the initial recognition of goodwill and temporary differences arising on the initial recognition of an asset or liability in a transaction which is not a business combination and at the time of the transaction affects neither accounting nor taxable profit or loss.

Recognition of deferred tax assets for unused tax losses, tax credits and deductible temporary differences is restricted to those instances where it is probable that future taxable profit will be available against which the deferred tax asset can be utilized. At the end of each reporting period the Company reassesses unrecognized deferred tax assets. The Company recognizes a previously unrecognized deferred tax asset to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

c) Financial instruments

On initial recognition financial assets are classified as measured at:

- i. Amortized cost;
- ii. Fair value through other comprehensive income ("FVOCI"); and
- iii. Fair value through profit and loss ("FVTPL").

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

Financial assets are not reclassified subsequent to their initial recognition unless the Company changes its business model for managing financial assets in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model.

At initial recognition, the Company measures a financial asset at its fair value plus, in the case of a financial asset not at FVTPL, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVTPL are expensed in profit or loss. Financial assets are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.

Subsequent measurement of financial assets depends on their classification:

i. Amortized cost

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. A gain or loss on a debt investment that is subsequently measured at amortized cost is recognized in profit or loss when the asset is derecognized or impaired. Interest income from these financial assets is included as finance income using the effective interest rate method.

The Company does not have any assets classified at amortized cost.

ii. FVOCI

Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains and losses, interest revenue, and foreign exchange gains and losses which are recognized in profit or loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains (losses). Interest income from these financial assets is included as finance income using the effective interest rate method.

c) Financial instruments (continued)

The Company does not have any assets classified at FVOCI.

iii. FVTPL

Assets that do not meet the criteria for amortized cost or FVOCI are measured at FVTPL. A gain or loss on an investment that is subsequently measured at FVTPL is recognized in profit or loss and presented net as revenue in the Consolidated Interim Statement of Loss and Comprehensive Loss in the period in which it arises.

The Company's cash is classified at FVTPL.

Financial Liabilities and Equity

Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangement. An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the group entities are recorded at the proceeds received, net of direct issue costs.

Financial liabilities are classified as measured at (i) FVTPL; or (ii) amortized cost.

A financial liability is classified as at FVTPL if it is classified as held-for-trading or is designated as such on initial recognition. Directly attributable transaction costs are recognized in profit or loss as

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

incurred. The amount of change in the fair value that is attributable to changes in the credit risk of the liability is presented in OCI and the remaining amount of the change in the fair value is presented in profit or loss.

The Company does not classify any financial liabilities at FVTPL.

Other non-derivative financial liabilities are initially measured at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method.

The Company classifies its accounts payable, loans payable, deferred revenue, amounts payable and convertible note at amortized cost.

A financial liability is derecognized when the contractual obligation under the liability is discharged, cancelled or expires or its terms are modified and the cash flows of the modified liability are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value.

d) Share capital

Common shares are classified as equity. Transaction costs directly attributable to the issue of common shares and common share warrants are recognized as a deduction from equity. Common shares issued for non-monetary consideration are measured based on their market value at the date the common shares are issued.

The Company has adopted the relative fair value method with respect to the measurement of common shares and warrants issued as equity units. The relative fair value method requires an allocation of the net proceeds received based on the pro rata relative fair value of the components. If and when the warrants are ultimately exercised, the applicable amounts are transferred from reserve for warrants to share capital.

e) Earnings (loss) per share

The Company presents basic and diluted earnings (loss) per share data for its common shares, calculated by dividing the earnings (loss) attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting the earnings attributable to common shareholders and the weighted average number of common shares outstanding for the effects of all dilutive potential common shares. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive. Basic and diluted loss per share is the same for the periods presented.

f) Impairment of long-lived assets

Long-lived assets, including intangible assets are reviewed for impairment at each statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the cash-generating unit, or "CGU"). The recoverable amount of an asset or a CGU is the higher of its fair value, less costs to sell, and its value in use. If the carrying amount of an asset exceeds its recoverable amount, an impairment charge is recognized immediately in profit or loss by the amount by which the carrying amount of the asset exceeds the

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

recoverable amount. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the lesser of the revised estimate of recoverable amount, and the carrying amount that would have been recorded had no impairment loss been recognized previously.

g) Intangible assets

Intangible assets consist mainly of trademarks, pending patents and prototype development costs, including certain intellectual property. Acquired trademarks, patents and development costs are carried at cost less accumulated amortization and impairment. Intangible assets with indefinite lives are not amortized but are tested annually for impairment. Any impairment of intangible assets is recognized in the statement of operation and comprehensive loss but increases in intangible asset values are not recognized.

Estimated useful lives of intangible assets are shorter of the economic life and the period the right is legally enforceable. The assets' useful lives are reviewed, and adjusted if appropriate, at each statement of financial position date.

h) Research and development

Research costs are expensed as incurred. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development to use or sell the asset. Other development expenditures are recognized in profit or loss as incurred.

i) Share-based payments

Share-based payments to employees and others providing similar services are measured at the estimated fair value of the instruments issued on the grant date and amortized over the vesting periods. Share-based payments to non-employees are measured at the fair value of the goods or services received or the fair value of the equity instruments issued if it is determined the fair value of the goods or services cannot be reliably measured, and are recorded at the date the goods or services are received. The amount recognized as an expense is adjusted to reflect the number of awards expected to vest. The offset to the recorded cost is to equity settled share-based payments reserve.

Consideration received on the exercise of stock options is recorded as share capital and the related equity settled share-based payments reserve is transferred to share capital. Charges for options that are forfeited before vesting are reversed from equity settled share-based payment reserve.

Share-based compensation expense relating to deferred share units is accrued over the vesting period of the units based on the quoted market price. As these awards can be settled in cash, the expense and liability are adjusted each reporting period for changes in the underlying share price.

i) Business acquisitions

The Company assesses whether an acquisition should be accounted for as an asset acquisition or a business combination under IFRS 3 Business Combinations. This assessment requires management to make judgments on whether the assets acquired and liabilities assumed constitute a business as defined in IFRS 3 and if the integrated set of activities, including inputs and processes acquired, is capable of being conducted and managed as a business and the Company obtains control of the business inputs and processes.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES (continued)

k) Convertible debt

Convertible debentures, where applicable, are separated into their liability and equity components using the effective interest method. The fair value of the liability component at the time of the issue is determined based on an estimated interest rate of the debentures without the conversion feature. The fair value of the equity component is determined as the difference between the face value and the fair value of the liability component.

4. ACCOUNTING STANDARDS, INTERPRETATIONS AND AMENDMENTS NOT YET EFFECTIVE

The Company has performed an assessment of new standards issued by the IASB that are not yet effective. The Company has assessed that the impact of adopting these accounting standards on its financial statements would not be significant.

5. INTANGIBLE ASSETS

	Development	Patent and		
	Costs	Trademarks	License	Total
	\$	\$	\$	\$
Balance, February 29, 2020	2,891,460	-	228,716	3,120,176
Additions	242,860	-	118,814	361,674
Impairment	(3,134,319)	-	(347,530)	(3,481,849)
Balance, February 28, 2021	1	-	-	1
Additions			-	
Balance, May 31, 2021	1	-	-	1

As at May 31, 2021, the intangible assets relate to the Company's vaporizer prototype and a license agreement for the vaporizer technology, which were both not available for use. Accordingly, no amortization has been recorded.

During 2021, the Company completed its annual assessment of the recoverable amount of the intangible assets and determined that the recoverable amount was lower than the carrying value. Accordingly, the Company recorded an impairment loss of \$3,481,849 to recognize the economic uncertainty of the development costs.

6. DEPOSIT

In prior periods, the Company had a balance that consisted of amounts paid per the terms of a non-binding letter of intent to form a joint venture for the purpose of developing, constructing, operating, maintaining, and managing a facility which will manufacture and distribute the Company's patented heat-not-burn pods exclusively for the Company.

During the first quarter of 2021, the Company wrote-off the deposit amount in full (\$121,588) to recognize the economic uncertainty related to forming the joint venture. There have been no subsequent changes to this balance as at May 31, 2021.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

7. RELATED PARTY BALANCES AND TRANSACTIONS

All related party transactions have occurred in the normal course of operations. Related party transactions occur and are recorded at the amounts agreed between the parties.

As at May 31, 2020, Poda had amounts payable to Invictus MD Strategies Corp. ("Invictus") of \$2,086,106. On November 8, 2018, Invictus and the Company completed a plan of arrangement to give effect to a spinout transaction. The amounts payable was unsecured, non-interest bearing, and have no fixed terms of repayment.

On March 30, 2021, Poda completed an assignment agreement (Note 8) with the Company. Pursuant to the Assignment Agreement, Poda assigned \$2,086,106 amounts payable to the Company. On March 30, 2021, the Company issued 20,862 preferred shares to extinguish liabilities totaling \$2,086,106.

On April 12, 2019, the Company acquired the rights to additional vaporizer-related intellectual property from the original founders of the Company (the "Inventors") on the terms and conditions set forth in an amended and restated royalties' agreement (the "Amended Agreement"). The Inventors and the Company previously entered into a royalties agreement dated April 19, 2015 (the "Original Agreement"), pursuant to which the Company agreed to pay royalties to the Inventors in the amount of 3% of the Company's gross revenues in relation to the commercialization of certain inventions (the "Original Inventions"). Since that time, the Inventors have developed certain additional vaporizer-related inventions (the "New Inventions") and in accordance with the terms and conditions of the Amended Agreement, the Company is granted a royalty-bearing exclusive license to commercialize, use, and sublicense the Original Inventions and the New Inventions. In exchange for the additional rights granted to the Company under the Amended Agreement, the Company has assigned the ownership of certain patents back to the Inventors and the royalty payable by the Company has been increased from 3% to 4.5%. The fair value of the patents assigned back to the Inventors was \$146,583.

Key management compensation

Key management is comprised of the Company's directors and executive officers. The Company incurred the following key management compensation during the periods ended May 31, 2021 and 2020:

	2021	2020
	\$	\$
Consulting and management fees	74,467	71,020
Share-based compensation	5,065	
	79,532	71,020

As at May 31, 2021, accounts payable includes \$23,100 (2020 - \$109,500) due to the directors of the Company and \$nil (2020 - \$nil) due to the Chief Financial Officer of the Company.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

8. ARRANGEMENT AGREMEENT

The Company and Poda entered into an Arrangement Agreement ("Arrangement Agreement") on February 8, 2021, pursuant to which the Company, by way of a court approved plan of arrangement under the provisions of Division 5 of Part 9 of the BCBCA acquired all of the issued and outstanding PODA Shares in exchange for Preferred Shares to be issued as consideration pursuant to the Plan of Arrangement (the "Arrangement"). Pursuant to the Arrangement, PODA Shareholders received Preferred Shares at a ratio of 1 Preferred Share for every 1,000 PODA Shares held. Fractional Preferred Shares will be issued to shareholders owning less than 1,000 PODA Shares. Preferred Shares entitle each holder to a restricted right to convert one (1) preferred share into 1,000 Common Shares upon certain events or automatically on the following terms: (i) 10% after twelve (12) months from approval of the Arrangement and (ii) 15% every three (3) months thereafter. The Arrangement was approved at the Meeting and PODA obtained regulatory approval on April 23, 2021, resulting in 42,784 preferred shares issued which are convertible into 42,784,000 common shares.

The Arrangement resulted in the shareholders of Poda acquiring control of the Company. Therefore, the transaction, has been accounted for as an acquisition of the Company by Poda. The transaction has been accounted for as a reverse take-over ("RTO") and the continuing entity for accounting purposes is PODA and the comparative figures represent those of Poda.

9. SHARE CAPITAL

Authorized Share Capital

The Company has an unlimited number of common shares and preferred shares without par value authorized for issuance.

Share Transactions

From the period of the Arrangement Agreement there were the following share capital transactions:

- (i) As a result of the Arrangement Agreement (Note 8), the Company issued 42,784 preferred shares to the former Poda Shareholders and Poda became a wholly owned subsidiary of the Company.
- (ii) A vendor of the PODA (Note 7) converted its debt totaling \$2,086,103 into 20,862 preferred shares of the Company.
- (iii) Certain insiders of the Company converted their debt of \$359,528 into 3,595,285 Common Shares.
- (iv) The Company closed a private placement and issued 19,500,000 Common Shares at \$0.025 per share for total proceeds of \$487,500 including one (1) share purchase warrant with an exercise price of \$0.10 for every Common Share issued expiring three (3) years from date of issuance.
- (v) The Company closed a private placement and issued 7,000,000 Common Shares at \$0.05 per share for total proceeds of \$350,000.
- (vi) The Company closed a private placement and issued 150,000 Special Warrants at \$0.05 per share for total proceeds of \$7,500.
- (vii) The Company closed a private placement and issued 2,500,000 units at a price of \$0.40 per unit, for for gross proceeds of \$1,000,000. Each unit consists of one subordinate voting share.

During the period ended May 31, 2020:

(i) There were no share capital transactions.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

9. SHARE CAPITAL (continued)

Warrants

The Company issued an aggregate of 27,000,000 warrants pursuant to a unit private placement and convertible debenture issued on December 9, 2020. Each warrant is exercisable into one common share of the Company at \$0.10 per common share for a period of three years from the date of issuance.

The Company issued an aggregate of 1,250,000 warrants pursuant to a unit private placement issued on May 21, 2021. Each warrant is exercisable into one common share of the Company at \$0.50 per common share for a period of two years from the date of issuance.

As at May 31, 2021, 28,250,000 warrants are outstanding with a weighed average exercise price of \$0.30 and a weighted average remaining contractual life of 2.3 years.

There were no warrant transactions during the period ended May 31, 2020.

Stock option plan

The Company has adopted a rolling incentive stock option plan (the "Option Plan") which provides that the Board of Directors of the Company may from time to time, in its discretion, and in accordance with the applicable stock exchange's requirements, grant to Directors, officers, employees or consultants to the Company, non-transferable options to purchase common shares. Pursuant to the Option Plan, the number of common shares reserved for issuance will not exceed 15% of the issued and outstanding common shares of the Company. Options granted under the Option Plan can have a maximum exercise term of 10 years from the date of grant. Vesting terms will be determined at the time of grant by the Board of Directors.

On October 31, 2020, the Company granted a total of 150,000 incentive stock options to certain officers, and other eligible persons of the Company. The options are exercisable, vesting on November 1, 2020, over a period of five years at a price of \$0.16 per share.

On January 15, 2021, the Company granted a total of 600,000 incentive stock options to certain officers, directors and other eligible persons of the Company. The options are exercisable, subject to vesting provisions, over a period of five years at a price of \$0.10 per share.

On March 30, 2021, the Company granted a total of 550,000 incentive stock options to advisors and other eligible persons of the Company. The options are exercisable, subject to vesting provisions, over a period of five years at a price of \$0.10 per share.

For the period ended May 31, 2021, the Company recognized share-based compensation of \$18,573 (2020: \$nil). A total of 987,133 incentive stock options were cancelled during the period.

The Company uses the Black-Scholes option pricing model to estimate the fair value for all share-based compensation. The weighted average assumptions used in this pricing model, and the resulting weighted average fair values per option, for the options granted during the periods ended May 31, 2021 and 2020, respectively, are as follows:

	2021	2020
(i) Risk-free interest rate	1.60%	1.60%
(ii) Expected life	5 years	5 years
(iii) Expected volatility	125%	125%
(iv) Expected dividend yield	0%	0%
(v) Expected forfeiture rate	0%	0%
(vi) Fair value per option	\$0.14	\$0.12

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

9. SHARE CAPITAL (continued)

Movements in the number of stock options outstanding and their related weighted average exercise prices are as follows:

		Weighted
		average
	Number of	exercise price
	options	\$
Outstanding, May 31, 2020	4,762,177	0.14
Granted	1,250,000	0.12
Cancelled	(987,133)	(0.01)
Outstanding, May 31, 2021	5,025,044	0.64

The following summarizes information about the stock options outstanding and exercisable as at May 31 2021:

	Outstanding			Exercisable	
	Weighted			Weighted	_
	average	Weighted		average	Weighted
	remaining	average		remaining	average
	contractual life	exercise price		contractual life	exercise price
Number of options	(years)	\$	Number of options	(years)	\$
831,855		0.16	831,855		0.16
2,943,190		0.16	2,943,190		0.16
150,000		0.16	150,000		0.16
600,000		0.10	-		0.10
500,000		0.10	=		0.10
5,025,044	2.9	1.10	3,925,044	2.9	1.10

10. FINANCIAL INSTRUMENTS AND RISKS

Fair values

Assets and liabilities measured at fair value on a recurring basis were presented on the Company's statement of financial position as at May 31, 2021, as follows:

		May 31, 2021		
	Carrying value \$	Level 1 \$	Level 2 \$	Level 3
Cash	1,032,818	1,032,818	-	-
			May 31, 2020	
	Carrying			
	value	Level 1	Level 2	Level 3
	\$	\$	\$	\$
Cash	37,219	37,219	-	-

The fair values of other financial instruments, which include accounts payable, deferred revenue and amounts payable, approximate their carrying values due to the relatively short-term maturity of these instruments.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

10. FINANCIAL INSTRUMENTS AND RISKS (continued)

Credit risk

Credit risk arises from cash held with banks and financial institutions, as well as credit exposure on any outstanding accounts receivable. The carrying amount of financial assets represents the maximum credit exposure.

Currency risk

Currency risk is the risk that changes in foreign exchange rates will affect the Company's income or the value of its holdings of financial instruments. The Company has minimal financial assets and liabilities held in foreign currencies.

Interest rate risk

Interest rate risk consists of two components:

- (i) To the extent that payments made or received on the Company's monetary assets and liabilities are affected by changes in the prevailing market interest rates, the Company is exposed to interest rate cash flow risk.
- (ii) To the extent that changes in prevailing market rates differ from the interest rate in the Company's monetary assets and liabilities, the Company is exposed to interest rate price risk.

Current financial assets and financial liabilities are generally not exposed to interest rate risk because of their short-term nature and maturity. The Company's amounts due to related parties are non-interest bearing.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company currently settles its financial obligations out of cash. The ability to do this relies on the Company raising equity financing in a timely manner and by maintaining sufficient cash in excess of anticipated needs.

11. CONVERTIBLE NOTE

On October 23, 2019, Poda issued convertible debenture for gross proceeds of up to \$550,000. The debenture bears interest at 12% and is secured against the personal property of Poda. In the event that Poda earns a profit during any fiscal guarter, the debenture holders shall have the option to require Poda to prepay a portion of the principal amount and accrued interest amount and in an amount equal to up to 20% of the amount of profit for such quarter. At any time prior to the maturity date of the convertible debenture, the debenture holders have the option to convert any portion of the outstanding principal amount and accrued interest amount at the lower conversion rate of: i) 1 common share of Poda for \$0.05 of the principal amount plus accrued interest amount remaining due or ii) 20% discount to the price per share for the most recent financing. On the maturity date, the balance of the principal amount shall automatically be converted into shares of Poda at the lower conversion rate of i) 1 common share of Poda for \$0.05 of the principal amount remaining due or ii) 20% discount to the most recent financing prior to the maturity date. The debenture matures thirty-six (36) months from the date of closing of the financing on October 23, 2019 and is payable on demand after maturity. On March 30, 2021, Poda completed an assignment agreement (Note 8) with the Company. Interest expense of \$26,262 (2020 - \$22,658) was expensed to the Consolidated Statements of Comprehensive Loss during the year ended January 31, 2021. As at May 31, 2021, the Company had received an aggregate principal amount of \$550,000 (2020 - \$550,000).

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

11. CONVERTIBLE NOTE (continued)

On December 9, 2020, the Company issued an unsecured convertible debenture for gross proceeds of \$187,500 which were received in March of 2021. The convertible debenture bears interest at 1%, matures in 36 months, and is payable on demand after maturity. At any time prior to the maturity date of the convertible debenture, the holder has the option to convert any portion of the outstanding principal amount and accrued interest amount at a conversion rate of one common share of the Company for \$0.025 of the principal amount plus accrued interest amount remaining due. The holders were issued an aggregate of 7,500,000 common share purchase warrants with an exercise price of \$0.10 for every common share issued expiring three years from date of issuance.

12. LOAN PAYABLE

(i) On August 15, 2020, the Company received a loan from the Canadian government's Canada Emergency Business Account ("CEBA") Program in the amount of \$40,000. On December 15, 2020, the Company received an additional CEBA Loan in the amount of \$20,000 under the CEBA Loan expansion programs.

The CEBA is a government guaranteed loan that is interest-free until December 31, 2022. The loan is available to help businesses with operating costs during COVID-19. Twenty-five percent of the loan amount is eligible for forgiveness as long as the business pays back seventy-five percent of the outstanding balance on or before December 31, 2022. If the business cannot pay back the loan by December 31, 2022, it can be converted into a three-year term loan at an interest rate of 5%.

13. CAPITAL MANAGEMENT

The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of all components of shareholders' equity.

The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board of Directors, will balance its overall capital structure through new share issuances or by undertaking other activities, as deemed appropriate under the specific circumstances.

The Company is not subject to externally imposed capital requirements and the Company's overall strategy with respect to capital risk management remains unchanged from the period ended May 31, 2021.

14. COMMITMENT

On December 16, 2019, the Company entered into a non-binding letter of intent ("LOI") to form a joint venture company in China for the purpose of developing, constructing, operating, maintaining, and managing a facility which will manufacture and distribute capsules exclusively for the Company. Pursuant to the LOI, the Company has committed to certain contributions to form the joint venture. As at May 31, 2021, the Company has advanced \$112,588 (2020 - \$94,500) as described in Note 6.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MAY 31, 2021 AND 2020

(Expressed in Canadian Dollars)

15. SUBSEQUENT EVENTS

The Company announced that it had closed a non-brokered financing of units on June 24, 2021. In connection with the closing, the Company issued 6,576,943 units at a price of \$0.70 per unit, for gross proceeds of \$4,603,860. Each unit consists of one subordinate voting share and one-half of one warrant. Each whole warrant entitles the holder to purchase one subordinate voting share of the Company, at an exercise price of \$1.00 per share, for a period of two years from the date of issuance. The warrants are transferrable. Cash Finder's fees of \$256,094 were paid and 351,849 Finder's warrants were issued in connection with the offering. Each Finder's warrant entitles the holder to purchase one subordinate voting share of the Company, at an exercise price of \$1.00 per share, for a period of two years from the date of issuance.